This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Today's Health Winners and Losers

Shares of Martek Biosciences (MATK) were among the best-performing health-related stocks Thursday, jumping 18% after the maker of algae-related nutritional products raised its first-quarter sales guidance.

The company now sees sales of $62 million to $63 million, up from an earlier view of $58 million to $59 million. Analysts polled by Thomson First Call expected sales of $58.4 million. Martek attributed the revised guidance to growth in sales of its core infant formula. Shares were trading up $5.07 to $33.26.

Shares of eResearch Technology (ERES) slumped 17% after the supplier of technology used by biotech companies posted solid fourth-quarter earnings but warned that first-quarter results would be below forecasts. The company also said its chief executive will retire by the end of the year. For the fourth quarter, eResearch earned $5.3 million, or 10 cents a share, on sales of $25.4 million. Analysts expected earnings of 8 cents a share and sales of $24.5 million. During the year-earlier period, the company earned $7 million, or 13 cents a share, on sales of $27.1 million.

Looking ahead, eResearch sees first-quarter earnings of 5 cents to 7 cents a share on sales of $21 million to $23 million. The guidance excludes stock-based compensation costs, which will lower earnings by a penny a share. Analysts project earnings of 10 cents a share and sales of $26.8 million.

The company said that Joseph Esposito plans to retire as CEO before the end of 2006. "In addressing the company's future needs for pursuing our next phase of growth and profitability, both the board and I believe it is an opportune time for new leadership to take eResearch to the next level," Esposito said in a prepared statement. Shares were trading down $2.95 to $14.81.

Shares of Dendrite (DRTE) fell 12% after the provider of software and services to the pharmaceutical industry posted fourth-quarter earnings that were below expectations. The company earned $21,000, or less than a penny a share, on sales of $108.4 million. On an adjusted basis, which excludes noncash amortization expense, the company earned $250,000, or 1 cent a share. Analysts expected earnings of 4 cents a share, with sales of $106.4 million. "The fourth quarter was a difficult experience as we did not execute properly and take full advantage of our many growth opportunities," the company said. A year ago, the company posted adjusted earnings of $9.7 million, or 22 cents a share, on sales of $104.8 million. Shares were trading down $1.76 to $12.60.

1 of 3

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,778.15 +421.28 2.43%
S&P 500 2,061.23 +48.34 2.40%
NASDAQ 4,748.3960 +104.0840 2.24%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs